2025.09.02 从行业分布来看，社保基金此次新进和增持的个股主要集中在生物医药、计算机、电子等热门赛道，也 恰恰是国家战略支持的重点方向，也是经济转型升级的关键领域。这一投资动向引起了市场广泛关注。 作为具备长期稳定盈利能力的社保基金，其每一步调仓都蕴含着深层的战略思考。那么，社保基金大幅 增持科技股背后，究竟有着怎样的逻辑？ 偏爱医药、计算机 社保基金素以"稳健"著称，其投资风格一向谨慎，注重价值投资和长期回报。近年来，这一稳健投资者 加大了对科技创新企业的布局力度。 截至二季度末，社保基金持有77家科创板上市公司股票，主要集中在电子、生物医药、机械设备、计算 机四大行业，分别有20家、13家、10家、11家公司。 持股数量方面，社保基金持股达到且超过1000万股的共有7只，持有传音控股（688036.SH）3826.4万 股，位居第一，其次为西部超导（688122.SH），为2058.1万股；持有珠海冠宇（688772.SH）、铁建重 工（688425.SH）、中科星图（688568.SH）、三一重能（688349.SH）、聚合材料（688503.SH）的股 份数量也超过1000万股。 从社保基金的 ...

Core Viewpoint - The Social Security Fund has significantly increased its holdings in technology stocks, particularly in the fields of biomedicine, computing, and electronics, reflecting a strategic shift towards sectors supported by national policies and economic transformation [2][6]. Group 1: Investment Trends - As of the end of Q2 2025, the Social Security Fund held 77 stocks from the Sci-Tech Innovation Board, with a total holding of 337 million shares valued at 15.37 billion yuan, having newly entered 19 stocks and increased holdings in 28 [2][3]. - The fund's investment is primarily concentrated in four sectors: electronics (20 companies), biomedicine (13 companies), machinery (10 companies), and computing (11 companies) [2][3]. - The fund's investment style is characterized by a cautious approach, focusing on value investment and long-term returns, with a notable increase in allocations to innovative technology companies [2][5]. Group 2: Sector Preferences - The Social Security Fund's top holdings include companies like Transsion Holdings (38.26 million shares) and Western Superconductor (20.58 million shares), with a significant preference for biomedicine and electric power equipment over electronics [3][4]. - In Q2, the fund increased its holdings in the electronics sector, particularly in Transsion Holdings, which saw an increase of 6.37 million shares, marking the largest increase among individual stocks [4][5]. - The fund's new investments in Q2 included 19 stocks, with a total increase of 45.09 million shares, focusing on high-growth sectors such as biomedicine and computing [7][9]. Group 3: Performance Metrics - The newly added stocks by the Social Security Fund showed strong performance, with median revenue growth of 25.7% and net profit growth of 28.14% in the first half of the year, outperforming the overall market [8][9]. - Specific companies like Yifang Biomedicine and Spring Medical have demonstrated significant revenue and profit growth, indicating the fund's focus on firms with improving performance metrics [10]. Group 4: Reduction in Holdings - In Q2, 38 stocks from the Sci-Tech Innovation Board were reduced in holdings by the Social Security Fund, with 24 of these experiencing reductions of over 1 million shares [11][12]. - Notable reductions included companies like Zekang Pharmaceutical and Longxin Technology, which saw significant price increases post-reduction, indicating potential market volatility [12].

Core Insights - The social security fund has newly invested in 19 stocks in the second quarter, focusing on high-performing sectors such as biomedicine, computers, and electronics, which are aligned with national strategic priorities and economic transformation [1][5] Investment Trends - As of the end of the second quarter, the social security fund held 77 stocks in the Sci-Tech Innovation Board, with a total holding of 337 million shares valued at 15.37 billion yuan, having newly entered 19 stocks and increased holdings in 28 stocks [1][2] - The fund's investment style is characterized by a cautious approach, emphasizing value investment and long-term returns, with a notable increase in allocations to technology innovation companies [1][2] Sector Focus - The fund's holdings are primarily concentrated in four sectors: electronics (20 companies), biomedicine (13 companies), machinery (10 companies), and computers (11 companies) [1] - In terms of stock count, the fund's top holdings include 7 stocks with over 10 million shares, with Transsion Holdings (382.64 million shares) leading, followed by Western Superconducting (205.81 million shares) [2] Performance Metrics - The newly added 19 stocks showed median year-on-year growth rates of 25.7% in revenue and 28.14% in net profit, significantly outperforming the overall market [6] - The fund's focus on biomedicine is evident, with 4 new investments in this sector, alongside 2 each in electronics, military, communications, and computers [6] Notable Stock Movements - The fund increased its holdings in several key stocks, including a significant increase of 6.37 million shares in Transsion Holdings, marking the largest single stock increase for the quarter [3][4] - Other notable increases include 5 stocks in the biomedicine sector and 4 in the computer sector, with specific increases exceeding 1 million shares [4][5] Reduction in Holdings - In the second quarter, 38 stocks on the Sci-Tech Innovation Board were reduced in holdings by the social security fund, with 24 of these seeing reductions of over 1 million shares [8] - Some stocks that were reduced have since experienced significant price increases, indicating a potential misalignment in the fund's timing of trades [8]

Core Points - The company is proposing to increase the total investment in the "New Drug Research and Development Project" from 1.809619 billion yuan to 1.8781177 billion yuan, utilizing 684.988 million yuan of previously unallocated funds for this purpose [3][4]. - The company plans to reappoint Lixin Certified Public Accountants (Special General Partnership) as the auditing firm for the fiscal year 2025, ensuring the audit of financial statements and internal controls [3][4]. Meeting Details - The meeting is scheduled for September 8, 2025, at 9:30 AM, located at 63 Zhangheng Road, Pudong New District, Shanghai [4]. - The voting will occur both on-site and online, with specific time slots for participation [4]. - The agenda includes signing in, announcing the number of shareholders present, reading meeting guidelines, electing vote counters, discussing and voting on proposals, and concluding with the announcement of results [4][5].

目 录 | 2025 | 年第一次临时股东会会议须知 | 3 | | --- | --- | --- | | 2025 | 年第一次临时股东会会议议程 | 6 | | 议案一 | 关于变更部分募集资金投资项目的议案 8 | | | 议案二 | 关于续聘 2025 年度审计机构的议案 9 | | 证券代码：688382 证券简称：益方生物 益方生物科技（上海）股份有限公司 2025 年第一次临时股东会会议资料 二〇二五年九月 益方生物科技（上海）股份有限公司 2025 年第一次临时股东会会议须知 为了维护公司全体股东的合法权益，确保股东会的正常秩序和议事效率，保 证会议的顺利进行，根据《中华人民共和国公司法》（以下简称《公司法》）、 《中华人民共和国证券法》（以下简称《证券法》）、《上市公司股东会规则》 以及《益方生物科技（上海）股份有限公司章程》（以下简称《公司章程》）等 相关规定，益方生物科技（上海）股份有限公司（以下简称"公司"）特制定本 次股东会会议须知： 一、股东会设会务组，由公司董事会秘书负责会议的程序安排和会务工作； 六、股东及股东代理人要求发言或提问时，不得打断会议报告人的报告或其 他股东及股东 ...

Company Overview - Yifang Biotechnology (Shanghai) Co., Ltd. is located in the China (Shanghai) Free Trade Zone and was established on January 11, 2013. The company went public on July 25, 2022. Its main business involves the research, production, and sales of innovative drugs, with 100% of its revenue coming from technology licensing and cooperation [1]. Stock Performance - On September 2, Yifang Biotechnology's stock fell by 5.07%, closing at 39.88 CNY per share, with a trading volume of 424 million CNY and a turnover rate of 2.47%. The company's total market capitalization is 23.064 billion CNY [1]. Fund Holdings - According to data from the top ten holdings of funds, one fund under Tongtai Fund has a significant position in Yifang Biotechnology. The Tongtai Health Theme Mixed A Fund (011002) held 37,200 shares in the second quarter, accounting for 5.42% of the fund's net asset value, making it the fourth-largest holding. The estimated floating loss for today is approximately 79,200 CNY [2]. Fund Performance - The Tongtai Health Theme Mixed A Fund (011002) was established on April 8, 2021, with a current scale of 6.1823 million CNY. Year-to-date, it has achieved a return of 58.54%, ranking 514 out of 8,184 in its category. Over the past year, it has returned 69.4%, ranking 1,288 out of 7,971. Since inception, it has incurred a loss of 34.95% [2]. Fund Manager Information - The fund managers for Tongtai Health Theme Mixed A are Ma Yi and Mai Jianpei. Ma Yi has a tenure of 11 years and 170 days, managing assets totaling 6.063 billion CNY, with the best return during his tenure being 41.66% and the worst being -0.61%. Mai Jianpei has been in the role for 114 days, managing 161 million CNY, with the best return of 40.5% and the worst of 8.55% during his tenure [2].

Investment Rating - The investment rating for the company is "Buy" and is maintained [10] Core Viewpoints - The company reported a revenue of 19.16 million yuan for the first half of 2025, an increase of 28.85% compared to the same period in 2024, with a net profit attributable to shareholders of -119 million yuan, improving from -214 million yuan in 2024 [2][5][13] - The company is actively expanding its authorized products, including commercial cooperation for Beifutini and the approval of Gexuolei [7] - The ongoing clinical pipelines are progressing well, targeting high-barrier therapeutic areas, which enhances competitiveness [8][13] Summary by Sections Revenue and Profitability - In the first half of 2025, the company achieved a revenue of 19.16 million yuan, up 28.85% year-on-year, primarily due to increased income from technology licensing and cooperation [2][13] - The operating cost for the same period was 2.49 million yuan, a decrease of 60.63% compared to 2024, leading to an improved net profit of -119 million yuan, compared to -214 million yuan in 2024 [13] Product Pipeline - Beifutini (Simena®) has received NMPA approval for both first and second-line treatment of NSCLC and has entered the National Medical Insurance Directory [7] - Gexuolei (Anfangning®) was transferred to Zhengda Tianqing in August 2023 and was approved for market in November 2024, with positive clinical results reported at the 2025 ASCO conference [7] Research and Development - The registration phase III clinical trial for Taragarestrant (D-0502) is actively progressing for ER-positive, HER2-negative breast cancer [8] - The company has completed a phase II clinical trial for D-0120 in China and initiated a phase II trial in the US [8] - The phase III clinical trial plan for D-2570 has been completed, with the first patient dosed in a phase II trial for ulcerative colitis [8] Financial Forecast - The company forecasts net profits attributable to shareholders of -246 million yuan, -253 million yuan, and -227 million yuan for 2025, 2026, and 2027, respectively, with corresponding EPS of -0.42 yuan, -0.44 yuan, and -0.39 yuan [8]

Group 1 - On August 28, Yifang Bio's stock fell by 2.08%, with a trading volume of 723 million yuan [1] - The financing data for Yifang Bio on the same day showed a financing purchase amount of 34.17 million yuan and a financing repayment of 38.78 million yuan, resulting in a net financing outflow of 4.61 million yuan [1] - As of August 28, the total balance of margin trading for Yifang Bio was 118 million yuan, which accounted for 0.75% of its market capitalization [1] Group 2 - As of June 30, Yifang Bio had 9,790 shareholders, a decrease of 7.28% from the previous period, while the average circulating shares per person increased by 7.85% to 40,990 shares [2] - For the first half of 2025, Yifang Bio reported revenue of 19.16 million yuan, representing a year-on-year growth of 28.85%, while the net profit attributable to shareholders was -119 million yuan, an increase of 44.25% year-on-year [2] - Among the top ten circulating shareholders as of June 30, 2025, several new institutional investors entered, including Huatai-PineBridge Innovation Medicine Mixed A and Hong Kong Central Clearing Limited [2]

Core Insights - The company reported a significant increase in revenue for the first half of 2025, achieving 19.16 million yuan, a 28.85% increase compared to the same period in 2024, primarily due to increased technology licensing and collaboration income [1][2] - The net profit attributable to shareholders improved to -119 million yuan, compared to -214 million yuan in the same period of 2024, indicating an enhancement in profitability [1][2] Revenue and Profitability - The company's revenue for the first half of 2025 was 19.16 million yuan, reflecting a 28.85% year-on-year growth, driven by increased technology licensing and collaboration income [2] - Operating costs decreased by 60.63% to 2.49 million yuan, contributing to the improved financial performance [2] - The net profit attributable to shareholders was -119 million yuan, an improvement from -214 million yuan in 2024, indicating a trend towards better profitability [2] Product Development and Pipeline - The company is actively expanding its authorized products, including: - **Befotertinib (赛美纳)**: Commercial collaboration with Betta Pharmaceuticals, with approvals for first/second-line treatment of NSCLC and inclusion in the National Medical Insurance Directory [4] - **Gosorestat (安方宁)**: Rights transferred to Zhengda Tianqing, with approval received in November 2024 and positive clinical results presented at the 2025 ASCO conference [4] - Ongoing research pipelines include: - **Taragarestrant (D-0502)**: Actively advancing in a Phase III clinical trial for ER-positive, HER2-negative breast cancer [5] - **D-0120**: Completed Phase IIb trial in China and initiated a Phase II trial in the US [5] - **D-2570**: Phase III trial protocol completed, with Phase II trial for ulcerative colitis having commenced [5] Financial Forecast - The company forecasts net profits attributable to shareholders of -246 million yuan, -253 million yuan, and -227 million yuan for 2025-2027, with corresponding EPS of -0.42 yuan, -0.44 yuan, and -0.39 yuan [5]

Core Viewpoint - The A-share market saw a significant rise in satellite communication concept stocks following the release of the Ministry of Industry and Information Technology's guidelines to promote the development of the satellite communication industry, aiming for over 10 million users by 2030 [1][2]. Group 1: Market Performance - Notable stocks include Chuangyi Information, which rose over 13%, and Zhenlei Technology and Huali Chuantong, both increasing over 10% [1]. - Other companies such as Xingwang Yuda and Fudan Microelectronics also experienced substantial gains, with increases nearing 10% and 8% respectively [1]. - The overall trend indicates a strong market response to the new policies, with various companies in the satellite communication sector showing positive performance [1]. Group 2: Policy Implications - The guidelines propose 19 measures to expand market access, enhance application scenarios, and foster a robust industry ecosystem [2]. - Key areas of focus include supporting low-orbit satellite internet development, enabling telecom operators to connect terminal devices directly to satellites, and conducting commercial trials for satellite IoT [2]. - The industry is expected to evolve into a new trillion-level market, with a clear policy direction and strategic importance highlighted by the government [2]. Group 3: Investment Opportunities - Analysts suggest monitoring investment opportunities in satellite communication service providers, satellite operation and services, satellite manufacturing, and ground equipment manufacturing [2]. - The report from CITIC Securities emphasizes the ongoing optimization of business access in the satellite communication sector, indicating a potential acceleration in license issuance [2].